United States

People: Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

18 Jan 2019
Change (% chg)

$0.13 (+0.82%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Southwell, David 

Mr. David. P. Southwell is President, Chief Executive Officer, Director of the Company. He served as our President and Chief Executive Officer from July 2014 to January 2018. From March 2010 to October 2012, Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, Inc., or Human Genome Sciences, which is owned by GlaxoSmithKline plc. Prior to his time at Human Genome Sciences, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Sepracor Inc. from July 1994 to July 2008. Mr. Southwell has also served on the Board of Directors of PTC Therapeutics Inc. since December 2005 and Spero Therapeutics, Inc. since February 2018. Mr. Southwell received a B.A. from Rice University and an M.B.A. from Dartmouth College. We believe that Mr. Southwell’s qualifications to sit on our Board include his broad experience serving on the boards of directors of public companies, his specific experience with public therapeutics companies and his executive leadership, managerial and business experience.

Basic Compensation

Total Annual Compensation, USD 719,316
Restricted Stock Awards, USD 533,750
Long-Term Incentive Plans, USD --
All Other, USD 14,016
Fiscal Year Total, USD 1,267,080

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --